I call the linked peer reviews of our successful Phase III trial successful.
But I also call the PREACH-M trial of lenzilumab's treatment of CMML successful. Once this blazes the pathway of regulatory success for lenz, I think the FDA will recognize the futility of trying to save the covid market for Pfizer. In fact, that's already a lost cause, no matter how much lipstick the FDA puts on the mRNA vaccines. The public is not buying the hype.
But, the public will need a real covid vaccine and covid therapeutic. They will need lenz.
We just need to announce some news, and take an interim step back onto the OTC pink venue.
Market Data 
Markets 
AI
